New Biosimilars And FDA Approvals Will Strengthen Future Market Presence

AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Published
12 Dec 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
₹382.90
10.3% undervalued intrinsic discount
07 Aug
₹343.35
Loading
1Y
1.9%
7D
-10.4%

Author's Valuation

₹382.9

10.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 9.56%

Shared on23 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has decreased revenue growth from 16.0% to 12.8%, increased profit margin from 6.9% to 7.8%, decreased future PE multiple from 41.9x to 35.6x and increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 2.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.32%

Shared on26 Mar 25
Fair value Decreased 4.98%

AnalystConsensusTarget has decreased future PE multiple from 42.7x to 38.0x and increased shares outstanding growth rate from -0.0% to 0.0%.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 23%

AnalystConsensusTarget has increased revenue growth from 14.3% to 16.1% and increased future PE multiple from 37.3x to 42.8x.